Optimización de la formación in situ formulaciones orales intragástrica con diferentes grados de PEG by Patel, RR & Patel, JK
Editorial
Martínez-Martínez F, Faus MJ, Ruiz-López MD.  
Originales
Design, development and optimization of buccal bioadhesive tablets of diclofenac 
sodium for the treatment of odontalgia
Edavalath S, Rao BP.   
RP-HPLC method for simultaneous estimation of atorvastatin calcium and ramipril 
from plasma
Mishra S, Suryawanshi R, Chawla V, Saraf S.
In-vitro studies of diclofenac sodium controlled-release dosage from biopolymeric 
hydrophilic matrices
Suriyaprakash TNK, Prabu SL, Satyam T.
Optimization of in situ forming intragastric oral formulations with different grades 
of PEGs 
Patel RR, Patel JK.
Development and characterization of Controlled Release Mucoadhesive Tablets 
of Captopril
Dalvadi HP, Patel JK, Rajput GC, Muruganantham V, Jayakar B.  
Especial
Guía de actuación para el farmacéutico comunitario en pacientes con hipertensión 
arterial y riesgo cardiovascular. documento de consenso (versión extendida).
Sabater-Hernández D, de la Sierra A, Bellver-Monzó O, Divisón JA, Gorostidi M, Perseguer-
Torregosa Z, Segura J, Tous S.
Ars Pharmaceutica
Ars Pharm. 2011; 52(2)









25Ars Pharm. 2011; 52(2): 25-30.
Optimization of in situ forming intragastric oral 
formulations with different grades of PEGs
Patel RR, Patel JK. 
Department of Pharmaceutics, Nootan Pharmacy College, S.P.Sahkar Vidhyadham, Visnagar, Gujarat, India.
Correspondence: Mr. Ravikumar R. Patel
Lecturer in Pharmaceutics Department,







The drug release profiles were optimized using different grades of polyethylene 
glycols (PEGs). Phase diagrams of ternary mixtures of ethylcellulose, PEG and 
TEC were obtained and used for optimization of drug release. The phase diagrams 
showed that addition of higher molecular weight of PEGs increased the phase 
separation and caused precipitation of ethylcellulose from the ternary mixtures. 
The effect of different grades and concentrations of PEGs in novel oral intragastric 
controlled release gel formulations were also investigated. In conclusion, the in 
situ forming oral controlled release formulations were successfully developed and 
the formulations were able to control the release of hydrochlorothiazide up to 24 
hours.
KEYWORDS: Ethylcellulose, PEG, TEC, Phase diagrams, Ternary mixtures, 
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RESUMEN
Los perfiles de liberación farmacológica se optimizaron mediante diferentes grados 
de glicoles de polietileno (PEGs). Se obtuvieron diagramas de fase de mezclas 
ternarias de etilcelulosa, PEG y TEC, que se usaron para optimizar la liberación 
farmacológica. Los diagramas de fase mostraron que la adicción de PEGs de mayor 
peso molecular incrementaba la separación de fases y causaba precipitación de 
etilcelulosa de las mezclas ternarias. Se investigó también el efecto de distintos 
grados y concentraciones de PEGs en nuevas formulaciones de geles orales de 
liberación controlada intragástrica. En conclusión, las formulaciones orales de 
liberación controlada in situ se desarrollaron con éxito y fueron capaces de controlar 
la liberación de hidroclorotiazida hasta 24 horas.
PALABRAS CLAVE: Etilcelulosa, PEG, TEC, Diagramas de fase, Mezclas ternarias, 
Hidroclorotiazida
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INTRODUCCIÓN
Polyethylene glycols (PEGs) have been widely used 
in a variety of pharmaceutical formulations including 
parenteral, topical, ophthalmic, oral and rectal preparations. 
PEGs are available in different molecular grades, and 
the physicochemical properties of these grades are quite 
different from one another (table1). High molecular 
weight PEGs (m.w. > 4000) have been used as binders 
and lubricants for soluble tablets, whereas, low molecular 
grade PEGs have been used for injectable, ophthalmic 
and nasal preparations. In addition, they have been used 
as plasticizers for polymers utilized for film coating and 
microencapsulation.1 PEGs and their derivatives have also 
been used as wetting and channeling agents to increase oral 
bioavailability of poorly soluble drugs such as rofecoxib,2 
ketoconazole,1 glibenclamide,3 prednisolone,4 and many 
more.5 Leonardi et al., have studied the stability of 
prednisolone solid dispersion in PEG 6000 using scanning 
electron microcopy (SEM), infrared (IR) spectroscopy, and 
X-ray powder diffraction techniques.6 The stability study 
showed that the drug was stable, without any interaction 
between the prednisolone and PEG 6000 at different 
stability conditions for one year. Similar results were 
reported for rofecoxib-PEG 4000 solid dispersions.2
In this study, unique in situ forming intragastric oral 
formulations (ISFIOFs) were prepared with a blend of a 
hydrophobic polymer, Ethocel and solvent (TEC). These 
formulations can be utilized as potential oral controlled 
drug delivery systems. Some of the advantages of the 
ISFIOFs are that they are easy to manufacture and scale 
up because of the less processing steps. In addition, they 
can also be developed as tamper-proof dosage forms of 
controlled substances, and drug release profiles can be 
easily modulated from these formulations by changing 
the formulation factors. However, the ability of these 
formulations to withstand mechanical stress is an 
important aspect of controlled release ISFIOFs in order 
to prevent dose dumping. Furthermore, the formulation 
should be able to release the entire drug during a specified 
time frame. In general, the mechanical strength of ISFIOFs 
can be increased by increasing the solid content such as, 
polymer concentration in the formulation. However, 
the drug release kinetics is strongly affected by changes 
in the polymer concentration. Therefore, to obtain a 
formulation with adequate mechanical strength and the 
one that provides optimum drug release is challenging. 
To overcome these challenges, different grades of PEGs 
were used as channeling and bulking agents for the ISFIOF 
formulations in this study. Upon addition of PEGs, the 
ISFIOFs are converted to ternary mixtures. For any stable 
ternary phase mixture, an adequate balance of hydrophilic 
and lipophilic molecules is essential. The relative amounts 
of three components in a system can be represented in a 
ternary phase diagram. Gibbs phase diagrams can be 
used to show the influence of changes in the weight or 
volume fractions of the different components on the phase 
behavior of the system.7 In a typical phase diagram, the 
three components comprising the system are each found at 
an apex of a triangle, where their corresponding weight or 
volume fraction is 100%. At any point away from the apex, 
the weight or volume fraction of a specific component is 
reduced, while the weight or volume fraction of one or 
both of the two other components is increased. Each point 
within the triangle represents a possible composition of a 
mixture of the three components. These points combine 
to form regions with boundaries between them, which 
represent the “phase behavior” of the system at constant 
Tabla1. Physical properties of different grades of PEGs.8
PEG grades Supplied form AMW (range) T (ºC) S-20ºC (%w/w) Viscosity* (cSt) LD (g/mL)
200 Liquid 190 to 210 - Complete 4.3 1.0921
300 Liquid 285 to 315 -15 to -8 Complete 5.8 1.0927
400 Liquid 380 to 420 4 to 8 Complete 7.3 1.0931
600 Liquid 570 to 630 15 to 25 Complete 10.8 1.0931
1000 Fused solid 950 to 1050 35 to 40 80 17.2 1.0927
1450 Flake 1305 to 1595 42 to 46 72 26.5 1.0919
3350 Granular powder 3015 to 3685 53 to 57 67 90.8 1.0926
4000 Granular powder 3600 to 4400 53 to 59 66 140.4 1.0926
4600 Granular 4140 to 5060 54 to 60 65 183.9 1.0926
6000 Granular 5400 to 6600 55 to 61 64 320 -
8000 Granular powder 7000 to 9000 55 to 62 63 821.7 1.0852
AMW: Average Molecular Weight; T: Melting or Freezing temperature; S-20: Solubility in water at 20ºC; LD: Liquid density at 60ºC 
* Viscosity at 100ºC; 
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temperature and pressure. The phase diagram can be used 
to identify regions in which the ternary phase is stable or 
uniform. Therefore, the objective of this study was to use 
the phase diagrams to identify the amounts of different 
grades of PEGs, which can be used to prepare novel 




Ethocel 10 FP and polyethylene glycols PEG 400, PEG 
1450, PEG 3350, PEG 4600 and PEG 6000 were obtained 
from Astron Chemical Ltd, Gujarat. Triethyl citrate 
(TEC) was obtained from Morflex Inc., Greensboro, 
NC. Hydrochlorothiazide (Torrent Research Center, 
Ahmedabad) was used as a model drug. 
Methods
1. Phase diagrams
Phase diagrams were constructed with different 
concentrations of different grades of polyethylene glycols 
(PEGs), namely, PEG 400, 1450, 3350, 4600 and 6000, Ethocel 
10 FP, and triethyl citrate (TEC). Blank gel formulations 
were prepared from different concentrations of Ethocel 
10 FP and TEC at 70oC. PEG was added to the resultant 
blank gel. The concentrations of the PEGs used in the gel 
formulations were 5, 10, 15, and 20% w/w, whereas the 
concentrations of Ethocel 10 FP were 5, 10, 15, 20, 25% 
w/w. The ternary blends, which yielded clear gels and the 
ones in which Ethocel precipitated were plotted as phase 
diagrams. The ratios of all the three ingredients, which 
formed a clear and uniform ternary blend at 70oC were 
identified from the phase diagrams, and controlled release 
drug loaded gel formulations were prepared using these 
ratios.
2. Formulation optimizations
In situ forming novel oral controlled release gel formulations 
(ISFIOFs) were prepared with different concentrations of 
Ethocel 10 FP, triethyl citrate (TEC) and different grades of 
polyethylene glycols, namely, PEG 400, 1450, and 3350. A 
total of 10 different formulations were prepared as listed 
in Table 2. The formulations were prepared as follows: 
Appropriate amounts of polymer (Ethocel 10 FP) and 
solvent (TEC) were mixed in a glass beaker and heated up 
to 70ºC with constant stirring. The polymers dissolved in 
the solvents and formed blank gels. Appropriate amounts 
of PEGs were then added to the resulting mixtures with 
continuous stirring. The PEGs melted in the blank gels and 
formed a homogeneous ternary mixture. The grades and 
concentrations of the PEGs were selected from the phase 
diagrams such that the resulting ternary system consisting 
of Ethocel 10 FP, PEG and TEC formed a clear blank gel. 
An appropriate quantity of hydrochlorothiazide was 
then added to the blank gel with continuous stirring. The 
resultant drug-loaded gel formulation was poured into a 
heated glass syringe, which was used as a capsule-filling 
device. Pre-weighed hard gelatin capsules, size 00, were 
filled with the gel formulation, capped and stored at room 
temperature until further use.
3. Determination of release profiles of hydrochlorothiazide
Drug release from three capsules of each drug-loaded gel 
formulation was evaluated using the USP Apparatus II at 
50 rpm. Phosphate buffer, pH 6.8 (900 ml) at 37 ± 0.5°C was 
used as the dissolution medium. Samples were taken at 1, 
2, 4, 6, 8, 10, 12, 16, 20, and 24 hours. Hydrochlorothiazide 
concentrations in the withdrawn samples were determined 
using a double beam UV-Spectrophotometer (Shimadzu, 
Model 1800) at 272 nm. The cumulative percentages of 
hydrochlorothiazide in the collected dissolution samples 
Table 2. Composition of formulations prepared with different grades of PEGs.
Batch number PEG grade
Composition of blank gels
Drug loading (% w/w)
PEG (%) Ethocel® 10 FP (%) TEC (%)
R1 3350 00 15 85 10
R2 3350 05 15 80 10
R3 3350 10 15 75 10
R4 3350 15 10 75 10
R5 3350 15 10 75 15
R6 3350 15 10 75 20
R7 1450 15 10 75 15
R8 400 10 15 75 15
R9 400 15 10 75 15
R10 400 25 10 65 15
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were calculated from the cumulative amount of drug 
released at specific time intervals and plotted.
RESULTS AND DISCUSSION 
1. Phase diagrams
Phase diagrams showed that addition of higher molecular 
weights of PEGs increased the phase separation and caused 
precipitation of ethylcellulose from the ternary mixtures of 
ethylcellulose, PEG and TEC (figures 1, 2, 3, 4 and 5). Gel 
formulations prepared from blends of ethylcellulose, TEC 
and PEG 400 gave a broader working range compared to 
those prepared from blends of ethylcellulose, TEC and PEG 
6000. For example, up to 30% PEG 400 could be incorporated 
into the gel formulations prepared with 10% Ethocel 10 FP 
and TEC without precipitation, whereas up to 15% PEG 
1450, 15% PEG 3350, 10% PEG 4600 or 5% PEG 6000 could 
be incorporated into the gel formulations prepared with 
10% Ethocel 10 FP and TEC without precipitation. Based 
on the phase separation studies, PEG 400, 1450 and 3350 
were selected for further studies. PEG 4600 and 6000 were 
not used for further studies due to their narrow working 
ranges.
2. Effect of different concentrations of PEG 3350
Since PEG 3350 is solid at room temperature and can be used 
as a bulking agent, initial gel formulations were prepared 
with PEG 3350. The release profiles of hydrochlorothiazide 
from the gel formulations prepared with 15% Ethocel 10 
FP, different concentrations of  PEG 3350 and TEC are 
shown in Figure 6. It is evident from the figure that as the 
PEG 3350 concentration increased from 0 to 10% in the gel 
formulation prepared with 15% Ethocel 10 FP, the drug 
release decreased from 72% to 50%, respectively, at 24 
hours. This is because, increasing the PEG content from 0 
to 10% increased the solid content of the gel formulation, 
thus resulting in faster precipitation of solid mass in the 
dissolution medium. Hence, burst release and overall drug 
release from the gel formulation prepared with PEG 3350 
was less than those prepared without PEG 3350.
Drug release form a rigid solid mass can be increased 
by creating pores and channels. Therefore, in order to 
increase the drug release from gel formulation prepared 
with blends of 15% Ethocel 10 FP, 10% PEG 3350 and TEC, 
the Ethocel 10 FP concentration in the abovementioned gel 
formulation was decreased from 15 to 10%, and the PEG 
3350 concentration was correspondingly increased from 10 
to 15%. These modifications of the gel formulations led to 
an increase in drug release from 50% (for gel formulation 
prepared with 15% Ethocel 10 FP, 10% PEG 3350 and TEC) 
to 84% (for gel formulation prepared with 10% Ethocel 10 
FP, 15% PEG 3350 and TEC) at 24 hours (Figure 6). 
Figure 2. Phase diagram of a tertiary system of Ethocel® 
10 FP, TEC and PEG 1450.
Figure 3. Phase diagram of a tertiary system of Ethocel® 
10 FP, TEC and PEG 3350.
Figure 1. Phase diagram of a tertiary system of Ethocel® 
10 FP, TEC and PEG 400.
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Figure 4. Phase diagram of a tertiary system of Ethocel® 
10 FP, TEC and PEG 4600.
Figure 5. Phase diagram of a tertiary system of Ethocel® 
10 FP, TEC and PEG 6000.
3. Effect of different grades of PEGs
Figure 7 shows drug release from gel formulations 
prepared with blends of 10% Ethocel 10 FP, 15% of two 
different grades of PEGs (PEG 1450 and PEG 3350) and 75% 
TEC. It is evident from the figure that a higher burst release 
(14% at 1 hours) was observed from the gel formulation 
prepared with the low molecular weight PEG 1450 than 
that prepared with the high molecular weight PEG 3350 
(6% at 1 hours). This was because the low molecular weight 
PEG 1450 leached out faster than PEG 3350 from the gel 
formulations.
However, after the first two hours, drug release from the gel 
formulation prepared with PEG 3350 was slower than that 
from gel formulation prepared with PEG 1450. This was 
because faster leaching out of the low molecular weight 
PEG 1450 from the gel formulation resulted in quicker 
precipitation of the Ethocel 10 FP on the exterior of the gel 
formulation and thus formation of a rigid shell around the 
gel. This rigid shell of precipitated Ethocel 10 FP retarded 
the penetration of the dissolution fluid into the solid mass 
thus resulting in slower drug release from gel formulation 
prepared with PEG 1450 (65% in 24 hours) compared to that 
prepared with PEG 3350 (95% in 24 hours). Gel formulation 
prepared with PEG 400 was dissipating in the dissolution 
medium and hence showed an erratic drug release profile 
(data not shown).
4. Effect of different drug loading
As the drug loading in the gel formulation prepared 
with 10% Ethocel 10 FP, 15% PEG 3350 and 75% TEC was 
increased from 10% to 20%, the drug release rate was 
also increased (Figure 8). For example, 84% of the drug 
was released in 24 hours from gel formulations prepared 
with 10% drug loading, whereas, 95% of the drug was 
Figure 6. Effect of PEG 3350 on drug release from gel 
formulations prepared with different concentrations 
of Ethocel® 10 FP and PEG 3350.
Figure 7. Effect of different grades of PEGs on drug 
release from gel formulations prepared with 10% 
Ethocel® 10 FP, 15% PEG 3350 and 75% TEC with 15% 
drug loading.
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Figure 8. Effect of different drug loadings on drug 
release from gel formulations prepared with 10% 
Ethocel® 10 FP, 15% PEG 3350 and 75% TEC
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released from the gel formulation prepared with 15% drug 
loading. However, 93% of drug was released in 10 hours 
from gel formulation prepared with 20% drug loading. 
The variation between drug release profiles of individual 
capsules was the highest from gel formulations prepared 
with 20% drug loading. However, the variation in all 
the drug release profiles were seen after 50% of the total 
amount of drug was released. A reproducibility study was 
performed on eight different capsules randomly selected 
from three different batches of optimized gel formulation 
(R5) in order to confirm the variability in the drug release 
profiles. 
Hence, this study showed that the rheology of the gel 
formulation prepared with 10% Ethocel 10 FP changed 
quickly. At the same time, the hydrophilic components 
such as the water-soluble drug, hydrochlorothiazide and 
the bulking agent, PEG 3350, in the gel formulation, also 
released continuously from the gel formulation. As a result, 
the total solid content of the gel formulation decreased. Both 
these phenomena, i.e. rheological changes, and the changes 
in the total solid contents altered the gel structure into a 
solid mass, initially at a slower rate, albeit at a controlled 
manner; while in the later stages, at a faster rate, but in 
an uncontrolled manner. Therefore, the final 30 to 40% of 
the drug was released in an erratic and an uncontrolled 
manner from the remaining solid mass. The solid mass 
remaining at the end of the dissolution study had sea-coral 
like structures with irregular pores and channels. The drug 
release profile also showed that the standard deviations of 
the drug release profiles increased after 50% of the drug 
was released from the gel formulation.
CONCLUSION
Phase diagrams of ternary mixtures of ethylcellulose, PEG 
and TEC were constructed and used for optimization of 
drug release from unique ISFIOF. Phase diagrams showed 
that addition of higher molecular weight PEGs increased the 
phase separation and caused precipitation of ethylcellulose 
from the ternary mixtures. Gel formulations prepared from 
blends of ethylcellulose, TEC and PEG 400 gave a broader 
working range compared to those prepared with blends of 
ethylcellulose, TEC and PEG 6000. Drug release from novel 
oral controlled release gel formulations were affected by 
different grades of PEGs. Drug release studies showed 
that low molecular weight PEG leached out faster from the 
gel formulation, thus giving higher burst release than that 
prepared with a high molecular weight PEG. Drug release 
from the optimized dosage form of ISFIOF, which was 
prepared with 10% Ethocel 10 FP, 15% PEG 3350, 75% TEC 
with 15% drug loading.
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